Abstract 73P
Background
Trophoblast cell surface antigen 2 (TROP2), or tumor-associated calcium signal transducer 2 TACSTD2, is a transmembrane transducer of intracellular calcium signal involved in tumor cell proliferation. Sacituzumab-govitecan a TROP2-targeting antibody-drug conjugate (ADC), is approved for breast cancer. Implications of TROP2 amplification (amp) in soft tissue sarcoma (STS) are understudied.
Methods
Amp defined by either CNV (Affymetrix single nucleotide polymorphism [SNP] 6.0 array data) or transcriptome (RNA-Seq_v2, log2- transformed RNA-Seq by expectation maximization [RSEM] normalized values) via cBioPortal. Query for amp of “TACSTD2” gene showed 494 samples of STS in 3 cohorts: Sarcoma TCGA, PanCancer Atlas – Cohort1, Sarcoma (MSKCC/Broad, Nat Genet 2010)- Cohort2 and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020) – Cohort3. For Cohort1, we extracted clinical data from TCGA Research Network; analysis of TCGA PanCancer Atlas with 2,922 pan-cancer cases was also evaluated.
Results
Cohort1 (253 patients) included dedifferentiated liposarcoma (DDLPS), myxofibrosarcoma (MFS), malignant peripheral nerve sheath tumor (MPNST), synovial sarcoma (SS), leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS). 7% (17/253) exhibited amp of TACSTD2/TROP2 glycoprotein. The DDLPS group included 59 samples, with 11 (19 %) patients with amp. DDLPS clinical data included: median age 62 years, 46 patients with retroperitoneum DDLPS, 20.5 cm median size. 22 patients had R0 surgery. For UPS, amp was observed in 3 cases (6%) of 50 patients. For 24 MFS cases, 4% had the amp. Although the cohort was enriched with LMS, only 2% presenting amp. Cohort2 (207 patients) included DDLPS (24.2%). 19 patients (9%) had amp. Cohort3 included 34 patients with either DDLPS or LMS. Of the cohort 9% presented with amp. 3 of 19 patients with DDLPS (16%). PanCancer Atlas consisted of 2,922 samples across 38 cancers. TROP2 amp detected in 32 samples (2 %). Liposarcoma exhibits the highest amp rate followed by bone cancer and breast cancer. These findings corroborate that patients with DDLPS are enriched for the amp.
Conclusions
Our results support prospective analysis of TROP2 amp in DDLPS clinical trials.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Pollack: Financial Interests, Personal, Invited Speaker: SpringWorks; Financial Interests, Personal, Advisory Board: Deciphera, Aadi. B. Vincenzi: Financial Interests, Personal, Invited Speaker: PharmaMar, Deciphera, Boehringer Ingelheim. P. Viveiros: Financial Interests, Personal, Invited Speaker: SpringWorks. All other authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract